0 207

Cited 0 times in

Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time

Authors
 Tai Yeon Koo  ;  Ju Han Lee  ;  Sang-Il Min  ;  Yonggu Lee  ;  Myung Soo Kim  ;  Jongwon Ha  ;  Soon Il Kim  ;  Curie Ahn  ;  Yu Seun Kim  ;  Jayoun Kim  ;  Kyu Ha Huh  ;  Jaeseok Yang 
Citation
 KIDNEY INTERNATIONAL, Vol.100(1) : 206-214, 2021-07 
Journal Title
KIDNEY INTERNATIONAL
ISSN
 0085-2538 
Issue Date
2021-07
MeSH
Graft Survival ; Humans ; Kidney Transplantation* / adverse effects ; Living Donors ; Republic of Korea ; United Kingdom ; United States ; Waiting Lists*
Keywords
HLA incompatible ; desensitization ; donor-specific antibody ; kidney transplantation ; waiting time
Abstract
HLA-incompatible living donor kidney transplantation (LDKT) is one of efforts to increase kidney transplantation opportunity for sensitized patients with kidney failure. However, there are conflicting reports for outcomes of HLA-incompatible kidney transplantation compared to patients who wait for HLA-compatible deceased donor kidney transplantation (DDKT) in the United States and United Kingdom. Waiting for an HLA-compatible DDKT is relatively disadvantageous in Korea, because the average waiting time is more than five years. To study this further, we compared outcomes of HLA-incompatible LDKT with those who wait for HLA-compatible DDKT in Korea. One hundred eighty nine patients underwent HLA-incompatible LDKT after desensitization between 2006 and 2018 in two Korean hospitals (42 with a positive complement-dependent cytotoxicity cross-match, 89 with a positive flow cytometric cross-match, and 58 with a positive donor-specific antibody with negative cross-match). The distribution of matched variables was comparable between the HLA-incompatible LDKT group and the matched control groups (waiting-list-only group; and the waiting-list-or-HLA-compatible-DDKT groups; 930 patients each). The HLA-incompatible LDKT group showed a significantly better patient survival rate compared to the waiting-list-only group and the waiting-list-or-HLA-compatible-DDKT groups. Furthermore, the HLA-incompatible LDKT group showed a significant survival benefit as compared with the matched groups at all strength of donor-specific antibodies. Thus, HLA-incompatible LDKT could have a survival benefit as compared with patients who were waitlisted for HLA-compatible DDKT or received HLA-compatible DDKT in Korea. This suggests that HLA-incompatible LDKT as a good option for sensitized patients with kidney failure in countries with prolonged waiting times for DDKT.
Full Text
https://www.sciencedirect.com/science/article/pii/S0085253821002581
DOI
10.1016/j.kint.2021.01.027
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Myoung Soo(김명수) ORCID logo https://orcid.org/0000-0002-8975-8381
Kim, Soon Il(김순일) ORCID logo https://orcid.org/0000-0002-0783-7538
Kim, Yu Seun(김유선) ORCID logo https://orcid.org/0000-0002-5105-1567
Lee, Ju Han(이주한)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184426
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links